
## Marie-Françoise Suaud-Chagny

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3634473/publications.pdf

Version: 2024-02-01



Marie-Françoise

#	Article	IF	CITATIONS
1	Examining Transcranial Direct-Current Stimulation (tDCS) as a Treatment for Hallucinations in Schizophrenia. American Journal of Psychiatry, 2012, 169, 719-724.	7.2	434
2	Effects of Fronto-Temporal Transcranial Direct Current Stimulation on Auditory Verbal Hallucinations and Resting-State Functional Connectivity of the Left Temporo-Parietal Junction in Patients With Schizophrenia. Schizophrenia Bulletin, 2016, 42, 318-326.	4.3	170
3	Sham tDCS: A hidden source of variability? Reflections for further blinded, controlled trials. Brain Stimulation, 2019, 12, 668-673.	1.6	137
4	Frontal Transcranial Direct Current Stimulation Induces Dopamine Release in the Ventral Striatum in Human. Cerebral Cortex, 2018, 28, 2636-2646.	2.9	133
5	Fronto-temporal transcranial Direct Current Stimulation (tDCS) reduces source-monitoring deficits and auditory hallucinations in patients with schizophrenia. Schizophrenia Research, 2015, 161, 515-516.	2.0	83
6	Microtubule Stabilizer Ameliorates Synaptic Function and Behavior in a Mouse Model for Schizophrenia. Biological Psychiatry, 2006, 60, 1224-1230.	1.3	81
7	How can cognitive remediation therapy modulate brain activations in schizophrenia?. Psychiatry Research - Neuroimaging, 2011, 192, 160-166.	1.8	75
8	Abnormal Striatal Dopamine Transmission in Schizophrenia. Current Medicinal Chemistry, 2013, 20, 397-404.	2.4	68
9	Dopaminergic transmission in STOP null mice. Journal of Neurochemistry, 2005, 94, 63-73.	3.9	65
10	Effects of acute metabolic stress on the dopaminergic and pituitary–adrenal axis activity in patients with schizophrenia, their unaffected siblings and controls. Schizophrenia Research, 2008, 100, 206-211.	2.0	65
11	Microdialysis monitoring of catecholamines and excitatory amino acids in the rat and mouse brain: recent developments based on capillary electrophoresis with laser-induced fluorescence detectiona mini-review. Cellular and Molecular Neurobiology, 2003, 23, 793-804.	3.3	54
12	SSR181507, A Dopamine D2 Receptor Antagonist and 5-HT1A Receptor Agonist. I: Neurochemical and Electrophysiological Profile. Neuropsychopharmacology, 2003, 28, 2064-2076.	5.4	51
13	Reduced Expression of STOP/MAP6 in Mice Leads to Cognitive Deficits. Schizophrenia Bulletin, 2013, 39, 969-978.	4.3	51
14	Chronic administration of atypical antipsychotics improves behavioral and synaptic defects of STOP null mice. Psychopharmacology, 2010, 208, 131-141.	3.1	49
15	In vivo monitoring of dopamine overflow in the central nervous system by amperometric techniques combined with carbon fibre electrodes. Methods, 2004, 33, 322-329.	3.8	47
16	Effects of repeated transcranial direct current stimulation on smoking, craving and brain reactivity to smoking cues. Scientific Reports, 2018, 8, 8724.	3.3	43
17	Integrity of the arcuate fasciculus in patients with schizophrenia with auditory verbal hallucinations: A DTI-tractography study. NeuroImage: Clinical, 2016, 12, 970-975.	2.7	40
18	Short- and long-term efficacy of electroconvulsive stimulation in animal models of depression: The essential role of neuronal survival. Brain Stimulation, 2018, 11, 1336-1347.	1.6	38

Marie-Françoise

#	Article	IF	CITATIONS
19	Pharmacology of electrically evoked dopamine release studied in the rat olfactory tubercle by in vivo electrochemistry. European Journal of Pharmacology, 1989, 164, 273-283.	3.5	37
20	Thalamus abnormalities during working memory in schizophrenia. An fMRI study. Schizophrenia Research, 2011, 125, 49-53.	2.0	31
21	Specific involvement of neurotensin type 1 receptor in the neurotensin-mediated in vivo dopamine efflux using knock-out mice. Journal of Neurochemistry, 2004, 89, 1-6.	3.9	28
22	On the involvement of a tonic dopamine D2-autoinhibition in the regulation of pulse-to-pulse-evoked dopamine release in the rat striatum in vivo. Naunyn-Schmiedeberg's Archives of Pharmacology, 1997, 355, 716-719.	3.0	26
23	Overexpression of complement component C4 in the dorsolateral prefrontal cortex, parietal cortex, superior temporal gyrus and associative striatum of patients with schizophrenia. Brain, Behavior, and Immunity, 2020, 90, 216-225.	4.1	25
24	Theta burst stimulation in the negative symptoms of schizophrenia and striatal dopamine release Schizophrenia Research, 2011, 131, 264-265.	2.0	23
25	Evidence that Activation of the Hypothalamo-Pituitary-Adrenal Axis by Electrical Stimulation of the Noradrenergic A1 Group Is Not Mediated by Noradrenaline. Neuroendocrinology, 1995, 62, 2-12.	2.5	17
26	Longitudinal MRI monitoring of brain damage in the neonatal ventral hippocampal lesion rat model of schizophrenia. Hippocampus, 2010, 20, 264-278.	1.9	17
27	Anodal tDCS targeting the left temporo-parietal junction disrupts verbal reality-monitoring. Neuropsychologia, 2016, 89, 478-484.	1.6	17
28	Post-pubertal emergence of alterations in locomotor activity in stop null mice. Synapse, 2007, 61, 689-697.	1.2	16
29	Widespread transcriptional disruption of the microRNA biogenesis machinery in brain and peripheral tissues of individuals with schizophrenia. Translational Psychiatry, 2020, 10, 376.	4.8	16
30	The neurotensin receptor antagonist SR 142948A blocks the efflux of dopamine evoked in nucleus accumbens by neurotensin ejection into the ventral tegmental area. Naunyn-Schmiedeberg's Archives of Pharmacology, 2002, 365, 427-433.	3.0	13
31	N-Acetyl-Aspartate in the dorsolateral prefrontal cortex in men with schizophrenia and auditory verbal hallucinations: A 1.5 T Magnetic Resonance Spectroscopy Study. Scientific Reports, 2018, 8, 4133.	3.3	13
32	Serotonergic response to stress: A protective factor against abnormal dopaminergic reactivity in schizophrenia?. European Psychiatry, 2007, 22, 362-364.	0.2	11
33	Distinct Expression Pattern of Epigenetic Machinery Genes in Blood Leucocytes and Brain Cortex of Depressive Patients. Molecular Neurobiology, 2019, 56, 4697-4707.	4.0	10
34	Serum Mature BDNF Level Is Associated with Remission Following ECT in Treatment-Resistant Depression. Brain Sciences, 2022, 12, 126.	2.3	10
35	Differential effects of desipramine on direct- and sensory-evoked noradrenaline release in thalamic locus coeruleus terminals. European Journal of Pharmacology, 1993, 235, 205-210.	3.5	9
36	Are basic auditory processes involved in source-monitoring deficits in patients with schizophrenia?. Schizophrenia Research, 2019, 210, 135-142.	2.0	8

Marie-Françoise

#	Article	IF	CITATIONS
37	Bayesian Estimation of the ntPET Model in Single-Scan Competition PET Studies. Frontiers in Physiology, 2020, 11, 498.	2.8	8
38	Examining transcranial random noise stimulation as an add-on treatment for persistent symptoms in schizophrenia (STIM'Zo): a study protocol for a multicentre, double-blind, randomized sham-controlled clinical trial. Trials, 2021, 22, 964.	1.6	7
39	Frontotemporal Transcranial Direct Current Stimulation Decreases Serum Mature Brain-Derived Neurotrophic Factor in Schizophrenia. Brain Sciences, 2021, 11, 662.	2.3	6
40	Neuroanatomical correlates of reality-monitoring in patients with schizophrenia and auditory hallucinations. European Psychiatry, 2021, 64, 1-28.	0.2	4
41	Left auditory cortex dysfunction in hallucinating patients with schizophrenia: An MEG study. Clinical Neurophysiology, 2013, 124, 823-824.	1.5	3
42	Abnormal Striatal Dopamine Transmission in Schizophrenia. Current Medicinal Chemistry, 2013, 20, 397-404.	2.4	3
43	Neurostimulation du cortex préfrontal dorsolatéralÂ: quels effets sur la symptomatologie, l'humeur et les émotions dans la dépression et la schizophrénie�. Sante Mentale Au Quebec, 0, 41, 223-239.	0.1	2
44	A Polysomnographic and Cluster Analysis of Periodic Limb Movements in Sleep of Restless Legs Syndrome Patients with Psychiatric Conditions. Psychiatry International, 2021, 2, 250-264.	1.0	0
45	The Future of Brain Stimulation to Treat Hallucinations. , 2013, , 513-527.		0